CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 106 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,069 | -99.3% | 340 | -99.7% | 0.00% | -100.0% |
Q4 2020 | $708,000 | -40.1% | 123,300 | -24.5% | 0.07% | -42.2% |
Q3 2020 | $1,182,000 | +56.6% | 163,300 | -24.5% | 0.12% | +68.1% |
Q2 2020 | $755,000 | +626.0% | 216,300 | +2603.8% | 0.07% | +392.9% |
Q1 2018 | $104,000 | – | 8,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |